Study ID: Roche BO27938 / NSABP B-50-I / GBG 77 (KATHERINE) Trial

A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy


The purpose of this study is to compare the effects, good or bad, of trastuzumab emtansine versus trastuzumab (Herceptin®) on participant¿s breast cancer to find out which is better. In this study, participants will get either trastuzumab emtansine or trastuzumab alone. Trastuzumab emtansine is an experimental drug, which means that health authorities have not approved trastuzumab emtansine for the treatment of HER2-positive primary non-metastatic breast cancer. Participants in this study have HER2-positive primary non-metastatic breast cancer and had evidence of cancer in the breast and lymph nodes after chemotherapy and trastuzumab.

Bemidji Clinic, Bismarck Region, Fargo Region
Principal Investigator:
Preston Steen, MD
Breast - Invasive
Phase III


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list